Background: The production of viral vaccines at commercial scale requires large quantities of viruses as an antigenic source. There are different production platforms suitable for viral replication -mammalian, avian and insect cells. Host cell residuals in the final product - nucleic acid in particular - create a significant concern due to a potential transfer and integration into the living cell's genetic material, potentially leading to various harmful effects including cancer. Health authorities and regulatory bodies continue to increase safety standards for biopharmaceutical products, providing stringent guidelines on removal of residual nucleic acid from the vaccine manufacturing processes.
展开▼
